Bristol-Myers Squibb Company (BMY) Is Driving Growth Through Strategic Acquisitions
US Federal Judge Dismisses $6.4 Billion Suit Against Bristol Myers Squibb
Bristol Myers Squibb Marks 10 Years of Global Patient Week With Community Initiatives in the Region
Sector Update: Health Care Stocks Steady Premarket Monday
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Ahead of Powell's Speech on Economic Outlook
Traders Consolidate Positions in Final Session for Q3, Driving Cautious Losses for US Equity Futures
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Sector Update: Health Care
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine Announces Strategic Research Collaboration and License Agreement With Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
US FDA Allows Trial of Sichuan Biokin Pharma-Bristol-Myers Squibb's Cancer Drug
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
【レーティング速報】ブリストル・マイヤーズ(BMY.US)のレーティング、最高60ドルまで
9月28日(米国時間)、ウォール街主要機関のアナリストが$Bristol-Myers Squibb(BMY.US)$のレーティングを更新し、目標株価は37ドルから60ドル。モルガン・スタンレーのアナリストTerence Flynnはレーティングを弱気に据え置き、目標株価を37ドルに据え置いた。J.P.モルガンのアナリストChris Schottはレーティングを強気に据え置き、目標株価を60ドルに据
每日空头追踪:Ambev SA(ABEV.US)卖空量激增472万,卖空成交比例达10%
J&J Releases Encouraging Data on Talvey Combination Therapies
Sector Update: Health Care Stocks Mixed Late Afternoon
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
La FDA Aprueba Un Medicamento Con Un Nuevo Mecanismo De Acción Para El Tratamiento De La Esquizofrenia
US Equity Indexes Mixed as Treasury Yields Slip After Investors Weigh Easing in Inflation
Bristol-Myers Squibb Potential Scalp Psoriasis Treatment Meets Targets